Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06605612Enrolling By Invitation

Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders

Role: collaborator

NCT04765124Unknown

The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy

Role: collaborator

NCT02395874Not ApplicableUnknown

tDCS and Speech Therapy to Improve Aphasia

Role: lead

NCT01274689Completed

External Lid Loading for the Temporary Treatment of the Paresis of the M. Orbicularis Oculi: a Clinical Note

Role: collaborator

All 4 trials loaded